Malta - English - Medicines Authority

medichem, s.a. fructuós gelabert 6-8, 08970, sant joan despí, (barcellona), spain - sugammadex - solution for injection - sugammadex 200 mg - all other therapeutic products

Malta - English - Medicines Authority

medichem, s.a. fructuós gelabert 6-8, 08970, sant joan despí, (barcellona), spain - sugammadex - solution for injection - sugammadex 500 mg - all other therapeutic products

Malta - English - Medicines Authority

pharmazac, s.a. 31 naousis str., 104 47, athens,, greece - sugammadex - solution for injection - sugammadex 200 mg - all other therapeutic products

Malta - English - Medicines Authority

pharmazac, s.a. 31 naousis str., 104 47, athens,, greece - sugammadex - solution for injection - sugammadex 500 mg - all other therapeutic products

European Union - English - EMA (European Medicines Agency)

piramal critical care b.v. - sugammadex sodium - neuromuscular blockade - sugammadex - reversal of neuromuscular blockade induced by rocuronium or vecuronium in adults.

United States - English - NLM (National Library of Medicine)

bio products laboratory limited - human immunoglobulin g (unii: 66y330cjhs) (human immunoglobulin g - unii:66y330cjhs) - gammaplex 5% is an immune globulin intravenous (human), 5% liquid indicated for replacement therapy in primary humoral immunodeficiency (pi) in adults and pediatric patients 2 years of age and older. this includes, but is not limited to, the humoral immune defect in common variable immunodeficiency, x-linked agammaglobulinemia (xla), congenital agammaglobulinemia, wiskott-aldrich syndrome, and severe combined immunodeficiencies. gammaplex 5% is indicated for the treatment of chronic immune thrombocytopenic purpura (itp) to raise platelet counts. - gammaplex 5% is contraindicated in patients who have had an anaphylactic or severe systemic reaction to the administration of human immune globulin. - gammaplex 5% is contraindicated in patients with hereditary intolerance to fructose, also in infants and neonates for whom sucrose or fructose tolerance has not been established. - gammaplex 5% is contraindicated in iga-deficient patients with antibodies to iga and a history of hypersensitivity. risk summary a

Malta - English - Medicines Authority

bio products laboratory limited dagger lane, elstree hertfordshire, wd6 3bx, united kingdom - immunoglobulin g, human - solution for injection - immunoglobulin g, human 5 % (w/v) - immune sera and immunoglobulins

European Union - English - EMA (European Medicines Agency)

mylan ireland limited - sugammadex sodium - neuromuscular blockade - all other therapeutic products - reversal of neuromuscular blockade induced by   rocuronium or vecuronium in adults.for the paediatric population: sugammadex is only recommended for routine reversal of rocuronium induced blockade in children and adolescents aged 2 to 17 years.

European Union - English - EMA (European Medicines Agency)

fresenius kabi deutschland gmbh - sugammadex sodium - neuromuscular blockade - all other therapeutic products - reversal of neuromuscular blockade induced by rocuronium or vecuronium in adults.for the paediatric population: sugammadex is only recommended for routine reversal of rocuronium induced blockade in children and adolescents aged 2 to 17 years.

European Union - English - EMA (European Medicines Agency)

aop orphan pharmaceuticals gmbh - sugammadex sodium - neuromuscular blockade - all other therapeutic products - reversal of neuromuscular blockade induced by rocuronium or vecuronium.for the paediatric population: sugammadex is only recommended for routine reversal of rocuronium induced blockade in children and adolescents aged 2 to 17 years.